23 Jan, 2024 Seize the moment: Contract manufacturers can address drug making challenges through tech, scale & diversification By Chris Taber David Simon Contract development and manufacturing organizations (CDMOs) play a critical role in the pharmaceutical and biotech industries, providing...
09 Jan, 2024 2024 AlixPartners Disruption Index: Finding a path to profitability By Simon Freakley Businesses have long had to cope with the impact of business cycles. Now they must address not just cycles but cyclones. In our findings...
12 Dec, 2023 CSRD reporting: How European pharma and healthcare firms can prepare By Veit Buetterlin Volker Popp Martin Born Oliver Pestalozzi +1 more... Show less A targeted analysis of European sector leaders provides indications of potential focus areas On January 5 2023, the EU Corporate Social...
31 Oct, 2023 Six critical success factors for healthcare buy-and-build strategies By Mark Veldon Maxim Vanhencxthoven Tendai Sibanda Buy-and-build (B&B) strategies are becoming increasingly common across the European healthcare space. For PE, the attraction of such...
13 Sep, 2023 Shareholder value creation in Japanese pharmaceuticals By Joji Hattori Ben Salcetti Sho Ogawa Tetsuya Kimura +1 more... Show less Many Japanese pharmaceutical companies have been languishing under low growth and profitability amid a ”triple whammy” business...
26 Jul, 2023 Know When to Fold ’Em: Bankruptcy Lessons from Akorn’s Chapter 7 By David Orlofsky Jon Baluzy As the current business cycle swings into volatile territory across the country, sponsors, lenders, and management teams will be faced...
15 May, 2023 Disruption Discussions: Balancing long-term disruptions with short-term demands By Simon Freakley Lisa Donahue David Garfield Rob Hornby +1 more... Show less In this video series, AlixPartners CEO Simon Freakley, Co-head of Asia & Americas Lisa Donahue, Head of EMEA Rob Hornby, and Head of...
15 May, 2023 How Midsize Companies Can Make the Most of Disruption By David Garfield Midsize companies face the same level of disruption as their larger rivals, but they are more likely to see themselves as disruption’s...
14 Dec, 2022 2023 AlixPartners Disruption Index: A bias for action sets growth leaders apart By Simon Freakley Lisa Donahue Rob Hornby David Garfield +1 more... Show less Our 4th annual survey reveals an urgency among executives to confront ongoing disruptors such as supply chain issues, energy shortages,...
06 Dec, 2022 The MedTech landspace – what next for this newly disrupted sector? By Philipp Bächtold Andri Fritz Lars Christopher Nientkewitz Oliver Pestalozzi +1 more... Show less The MedTech industry historically has been one of the more stable sectors. But, with multiple disruptive forces now at play, no one is...
23 Aug, 2022 Cyber Healthcare Series: Three imperatives that should define your medical device security strategy By Beth Musumeci Stanley Awenlimobor Leo Berrun Forty million – this is the stark number of individuals impacted by reported cybersecurity breaches from 697 healthcare entities between...
31 Jan, 2022 2022 AlixPartners Disruption Index: Taking control in a disrupted world By Simon Freakley How the new realities of demographics, deglobalization, climate change, and technological acceleration are transforming the world economy.